Concomitant chemiotherapy of irinotecan plus cisplatin and conformal therapy for non-small cell lung cancer

张洪; 王瑾; 周晓娟; 李燕; 沈娅丽; 王辛; 钟仁明

您当前的位置：

首页 >

文章列表页 >

Concomitant chemiotherapy of irinotecan plus cisplatin and conformal therapy for non-small cell lung cancer

更新时间：2026-01-09

- Concomitant chemiotherapy of irinotecan plus cisplatin and conformal therapy for non-small cell lung cancer
- Journal of Army Medical University Vol. 30, Issue 18, Pages: 1759-1761(2008)
- 作者机构：
- 作者简介：
- 基金信息：
- DOI：
  CLC： R730.53;R730.55;R737.9
- Published：2008
- 稿件说明：
移动端阅览
张洪,王瑾,周晓娟,李燕,沈娅丽,王辛,钟仁明.伊立替康联合顺铂加同期适形放疗治疗12例非小细胞肺癌[J].陆军军医大学学报(原第三军医大学学报),2008,30(18):1759-1761.

　ZHANG Hong,WANG Jin,ZHOU Xiao-juan,LI Yan,SHEN Ya-li,WANG Xin,ZHONG Ren-ming.Concomitant chemiotherapy of irinotecan plus cisplatin and conformal therapy for non-small cell lung cancer[J].J Amry Med Univ (J Third Mil Med Univ),2008,30(18):1759-1761.
张洪,王瑾,周晓娟,李燕,沈娅丽,王辛,钟仁明.伊立替康联合顺铂加同期适形放疗治疗12例非小细胞肺癌[J].陆军军医大学学报(原第三军医大学学报),2008,30(18):1759-1761. DOI：

　ZHANG Hong,WANG Jin,ZHOU Xiao-juan,LI Yan,SHEN Ya-li,WANG Xin,ZHONG Ren-ming.Concomitant chemiotherapy of irinotecan plus cisplatin and conformal therapy for non-small cell lung cancer[J].J Amry Med Univ (J Third Mil Med Univ),2008,30(18):1759-1761. DOI：

摘要

目的探讨伊立替康/顺铂联合影像引导放疗对非小细胞肺癌(non-small cell lung cancer，NSCLC)的疗效和可行性。方法晚期NSCLC患者，行为状态评分为 0～1，化疗方案为顺铂75 mg/m

（分3次于第1~3天给药）

伊立替康设3个剂量组（50、60、70 mg/m

）

分别于第1、8、15天给药，28 d重复，共给予2～3个周期，同期采用kV-CBCT引导3D适形胸部放疗[2.0 Gy/(次·d)，总剂量 66 Gy

]

。结果伊立替康最大耐受剂量为60 mg/m

剂量限制毒性为中性白细胞减少和食管炎。肿瘤缓解率75%，中位生存期11.5个月

随访未观察到症状性肺炎或食管炎发生。结论 Ⅲ期NSCLC患者采用胸腔图像引导3D适形放疗66 Gy联合同步伊立替康加顺铂化疗（伊立替康60 mg/m

，顺铂75 mg/m

），能为患者耐受。

Abstract

Objective To study the feasibility of irinotecan plus cisplatin and image-guided radiotherapy in treatment of advanced non-small cell lung cancer (NSCLC). Methods Twelve patients with locally advanced NSCLC and a performance status of 0 or 1 were eligible. The protocol consisted of escalating doses of irinotecan on days 1

8 and 15

and cisplatin (75 mg/m

administered equal split doses on days 1-3) for a total of 2 to 3 cycles combined with concurrent kV-CBCT guided 3D conformal radiotherapy (2.0 Gy daily for a total dose of 66 Gy). Results The maximum tolerable dose o

f irinotecan was 60 mg/m

and the dose-limiting toxicity was neutropenia and esophagitis. Tumor response was observed in 75% cases. The median survival time of the 12 patients enrolled was 11.5 months

and no symptomatic pneumonitis or esophagitis presented. Conclusion Accompanied by conformal therapy

the tolerated dose that irinotecan at 60 mg/m

on days 1

and cisplatin at 75 mg/m

is recommended for phase Ⅱ trial.

关键词

Keywords

references

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Effect of irinotecan combined with platinum first-line chemotherapy on brain metastasis of small cell lung cancer

Clinical analysis of chemoradiotherapy combined with bisphosphonates treatment on vertebral metastasis from small cell lung cancer

Related Author

Weiling CHEN

Xin LI

Zhujun CHEN

Pan LIU

Chunlan TANG

Liang GONG

冯燕

晁瑞

Related Institution

Department of Respiratory and Critical Care Medicine, First Affiliated Hospital, Army Medical University (Third Military Medical University)

⁰